GOLDSTONE ASIA PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 96.7659 million yuan, an increase of 66.47%
I'm PortAI, I can summarize articles.
GOLDSTONE ASIA PHARM released its third-quarter report for 2025, with operating revenue of 707.8 million yuan in the first three quarters, a year-on-year decrease of 6.37%. The net profit attributable to the parent company was 96.7659 million yuan, a year-on-year increase of 66.47%; the net profit excluding non-recurring gains and losses was 79.0115 million yuan, a year-on-year increase of 51.82%. The basic earnings per share were 0.24 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments